Search Results - neurologic+disease

41 Results

Sort By:

Antisense oligonucleotides to prevent genetic mis-splicing for ALS/FTD therapeutics

SHORT DESCRIPTION Antisense oligonucleotides (ASOs) that correct TDP‑43–dependent mis‑splicing of KCNQ2 thereby reducing neuronal hyperexcitability in ALS/FTD and related TDP‑43 proteinopathies. INVENTORS Evangelos Kiskinis* Northwestern University Feinberg School of Medicine, Department of Neurology Jonathan...

Published: 5/7/2026 | Updated: 5/7/2026 | Inventor(s):

Keywords(s): ALS - Amyotrophic Lateral Sclerosis, FTD - Frontotemporal Dementia, Neurodegenerative disease, Neurologic disease, Neurology, Nucleic Acids, Rare diseases, Targeted therapy, Therapeutics

Category(s): Life Sciences > Therapeutics

Northwestern Startup: Acumen Pharmaceuticals, Inc.

Founded: 1996 Northwestern Inventor: William Klein Weinberg College of Arts and Sciences Department of Neurobiology and Physiology Grant Krafft Feinberg School of Medicine Department of Molecular Pharmacology and Biological Chemistry Acumen Pharmaceuticals develops therapeutics for Alzheimer's Disease (AD) based upon the discovery and characterization...

Published: 5/7/2026 | Updated: 5/7/2026 | Inventor(s):

Keywords(s): Antibody, Neurodegenerative disease, Neurologic disease, Therapeutics

Category(s): Life Sciences > Therapeutics, Life Sciences > Healthcare Devices, Tools & IT

GDNF-Mimetic Self-Assembling Supramolecular Nanostructure to Enhance Survival and Function of Dopaminergic Neurons for Treatment of Parkinson's Disease

NU 2024-175 SHORT DESCRIPTION A self-assembling bioactive matrix that presents GDNF-mimetic peptides to support the viability, maturation, and function of dopaminergic neurons in cell replacement therapy for treatment of Parkinson’s Disease. INVENTORS Samuel Stupp* Weinberg College of Arts and Sciences, Department...

Published: 5/1/2026 | Updated: 4/30/2026 | Inventor(s):

Keywords(s): Biologic, Biomaterials, Cell delivery, CNS - Central Nervous System, CVA - Cerebrovascular Accident, Nanomaterials, Neurodegenerative disease, Neurologic disease, Neurology, PD - Parkinson's Disease, Scaffold, SCI - Spinal cord injury, TBI - Traumatic brain injury, Therapeutics

Category(s): Life Sciences > Therapeutics, Life Sciences > Biomarkers & Biomedical Research Tools, Life Sciences > Healthcare Devices, Tools & IT > Neurology

STING Agonist 8803 for Blood-Brain Barrier Opening in Glioblastoma Treatment

SHORT DESCRIPTION Chemical compound that opens the blood-brain barrier to enhance delivery of therapeutics for treating glioblastoma. INVENTORS Amy Heimberger* Northwestern University Feinberg School of Medicine, Department of Neurological Surgery * Principal Investigator NU Tech ID: NU 2025-212 IP...

Published: 5/7/2026 | Updated: 4/27/2026 | Inventor(s):

Keywords(s): AD - Alzheimer’s Disease, Adjunct therapy, ALS - Amyotrophic Lateral Sclerosis, Animal Model, Autoimmune disease, Bladder cancer, Brain cancer, Breast cancer, Cancer Treatment, Cancer/Oncology, Cervical cancer, CNS - Central Nervous System, Colon cancer, Drug delivery, Endometrial cancer, Gastric cancer, GBM - Glioblastoma, Head and neck cancer, Immunology, Immunotherapy, Liver cancer, Lung cancer, MS - Multiple Sclerosis, Neurodegenerative disease, Neurologic disease, Ovarian cancer, Pancreatic cancer, PD - Parkinson's Disease, Prostate cancer, Repurposed Drugs, Research tool, Small molecule, Targeted therapy, TBI - Traumatic brain injury, Therapeutics

Category(s): Life Sciences > Therapeutics, Life Sciences > Biomarkers & Biomedical Research Tools

Selective PAD2 Inhibitors for Neuroprotection in Traumatic Brain Injury

SHORT DESCRIPTION Novel PAD2-selective inhibitor platform targeting neuroinflammation to support both acute neuroprotection and long-term functional recovery as a first-in-class treatment of traumatic brain injury. INVENTORS Hasan Alam* Northwestern University Feinberg School of Medicine, Department of Surgery (Trauma...

Published: 5/1/2026 | Updated: 4/27/2026 | Inventor(s):

Keywords(s): CNS - Central Nervous System, CVA - Cerebrovascular Accident, Neurodegenerative disease, Neuroinflammation, Neurologic disease, Neurology, Small molecule, Targeted therapy, TBI - Traumatic brain injury, Therapeutics

Category(s): Life Sciences > Therapeutics

Biomolecular Condensates as Protein Degradation Tools for Intracellular Targets

SHORT DESCRIPTION A targeted-protein degradation platform for intracellular targets, addressing resistant oncogenic and neurodegenerative targets. INVENTORS Shana Kelley* Weinberg College of Arts & Sciences, Department of Chemistry Yi Li * Principal Investigator NU Tech ID: NU 2025-050 IP...

Published: 5/7/2026 | Updated: 4/27/2026 | Inventor(s):

Keywords(s): AD - Alzheimer’s Disease, Biologic, Biomolecular condensates, Cancer/Oncology, Drug delivery, Nanoparticle, Neurodegenerative disease, Neurologic disease, Neurology, PD - Parkinson's Disease, Platform technology, Targeted protein degradation, Targeted therapy, Therapeutics

Category(s): Life Sciences > Therapeutics, Life Sciences > Biomarkers & Biomedical Research Tools

Mitigating aberrant Cdk5 Activation in SMA – A Novel Therapeutic Strategy Targeting Mitochondrial Function

SHORT DESCRIPTION A targeted strategy that mitigates aberrant Cdk5 activity to restore mitochondrial function and reduce motor neuron degeneration in SMA models. INVENTORS Yongchao Ma* Northwestern University Feinberg School of Medicine, Department of Pediatrics * Principal Investigator NU Tech...

Published: 5/7/2026 | Updated: 4/27/2026 | Inventor(s):

Keywords(s): Adjunct therapy, Neurodegenerative disease, Neurologic disease, Neurology, Rare diseases, SMA - Spinal muscular atrophy, Targeted therapy, Therapeutics

Category(s): Life Sciences > Therapeutics

Inhibitors of TRIP8b for Novel Mood Disorder Therapeutics

SHORT DESCRIPTION For mood disorder treatment, these novel inhibitors disrupt TRIP8b-HCN binding to offer an alternative antidepressant mechanism. INVENTORS Gary Schiltz* Weinberg College of Arts and Sciences, Department of Chemistry Dane Chetkovich Ye Han Iredia Iyamu Kyle Lyman * Principal...

Published: 4/27/2026 | Updated: 4/27/2026 | Inventor(s):

Keywords(s): Antidepressant, Depression, Mood disorder, Neurologic disease, Neurology, Psychiatric disease, Targeted therapy, Therapeutics

Category(s): Life Sciences > Therapeutics

Nano-therapeutics Targeting Cholesterol Efflux Transporter in Macrophages for Cancer Immunotherapy

NU 2025-160 INVENTORS Jason Miska* Feinberg School of Medicine, Department of Neurological Surgery Peng Zhang* Feinberg School of Medicine, Department of Neurological Surgery SHORT DESCRIPTION Novel nanoparticle technology that modulates macrophage cholesterol metabolism to boost anti-tumor immunity in GBM. BACKGROUND Glioblastoma...

Published: 4/16/2026 | Updated: 4/14/2026 | Inventor(s):

Keywords(s): Adjunct therapy, Brain cancer, Cancer/Oncology, CNS - Central Nervous System, Drug delivery, Immunotherapy, Nanoparticle, Neurologic disease, Therapeutics

Category(s): Life Sciences > Therapeutics

JNK Inhibitors Targeting Bergmann Glia Inflammation to Mitigate Spinocerebellar Ataxia and Other Neurodegenerative Disorders

SHORT DESCRIPTION Novel therapeutic strategy targeting Bergmann glia inflammation using JNK inhibition for treatment of spinocerebellar ataxia type 1 (SCA1) and other neurodegenerative disorders. INVENTORS Puneet Opal* Northwestern University Feinberg School of Medicine, Professor of Neurology Chandrakanth...

Published: 5/7/2026 | Updated: 4/14/2026 | Inventor(s):

Keywords(s): Bergmann glia inflammation, Neurodegenerative disease, Neuroinflammation, Neurologic disease, Neurology, Rare diseases, SCA - Spinocerebellar ataxia, Small molecule, Therapeutics

Category(s): Life Sciences > Therapeutics

1 2 3 4 5